Moving beyond the hype: the reality of NGS in oncology today and in the future | Diaceutics

Moving beyond the hype: the reality of NGS in oncology today and in the future

May 25th, 2017

Jordan Clark
Peter Krein
Dr. Vincent Funari


Has Next Generation Sequencing lived up to the hype of industry predictions?

Join our next webinar to get a unique insight into the real-world use of NGS in the clinical setting. What are the opportunities and challenges of its implementation and how will this affect future adoption and utility?

This collaborative discussion between Diaceutics and NeoGenomics Laboratories will shed light on the clinical and commercial reality of NGS in oncology with predictions for what lies ahead. To attend register below.

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications